期刊文献+

云南汉族人群VKORC1 1173C/T基因多态性与华法林抗凝治疗维持剂量的相关性研究

Relationship between Genetic Polymorphism of VKORC1 1173C/T and Warfarin Dose Requirments in Yunnan Han Population
下载PDF
导出
摘要 目的研究云南汉族人群维生素K环氧化物还原酶复合体亚单位1基因VKORC1 1173C/T多态性分布及与其他群体间的差异,并探讨其与华法林抗凝维持剂量的分子遗传关系.方法采集300名心脏机械瓣膜置换术后服用华法林抗凝已达稳定剂量、凝血酶原时间国际标准化比值在目的范围(1.5~3.0)病人的外周血,采用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)分析技术,检测VKORC1 1173C/T基因位点的基因型和等位基因频率,探讨华法林抗凝维持剂量与该基因多态性的关系.结果在所有的样本中,VKORC1 1173C/T基因共检出C(10%)和T(90%)2种等位基因,纯合子TT(80%)和杂合子CT(20%)两种基因型,云南汉族人群中VKORC1 1173C/T基因多态性分布在性别和年龄上无差异;CT基因型病人所需华法林维持剂量最高(3.62±1.35)mg/d,其次是TT基因型病人(3.12±1.17)mg/d.结论与其他群体相比,云南汉族人群VKORC11173C/T基因位点具有自己的遗传多态性,其基因型在华法林抗凝治疗中具有非常重要的意义. Objective To investigate the polymorphism distribution and characteristics of VKORC1 1173C/T, as well as the relationship between the polymorphism and warfarin dose requirments in Han population in Yunnan. Methods Blood samples were collected from 300 patients with stable warfarin dose requirements, PCR-RFLP techniques were used to detect genes and genotypes of VKORC1 1173C/T, and international normalized ratio (INR) of the prothrombin time within the target range (1.5-3.0) , polymorphisms for VKORC1 1173CfI' were also analyzed. Results We obtained two alleles of C and T, with the frequencies of 10% and 90% , respectively. The genotypes showed that 80% patients were homozygous TI; and 20% were heterozygous CT. No differences were found between age and gender. Patients with CT genotypes required higher warfarin dose (3.62 ±1.35 mg/day) than those with TT (3.12 ± 1.17 mg/day; CT:TT p =0.007). Conclusion VKORC1 1173C/T gene distribution in Yunnan Han is different from those in other populations, and some suggestions are given for individual use of warfarin in Yunan Han population.
出处 《昆明医学院学报》 2012年第6期13-17,共5页 Journal of Kunming Medical College
基金 国家自然科学基金资助项目(30860339) 云南省社会发展科技计划项目(2009ZC155M)
关键词 云南地区 汉族 华法林 VKORC1 基因多态性 Yunnan Han Warfarin VKORC 1 Genetic polymorphism
  • 相关文献

参考文献14

  • 1AITHAL G P, DAY C P,KESTEVEN P J,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications[ J ]. Lancet, 1999,353:717 - 719.
  • 2HIGASHI M K,VEENSTRA D L,KONDO L M,et al. Association between CYP2C9 genetic variants and antico- agulatlon-related outcomes during warfarin therapy [J]. JAMA, 2002,287 : 1 690 - 1 698.
  • 3NASU K, KUBOTA T, ISHIZAKI T. Genetic analysis of C- YP2C9 polymorphism in a Japanese population [J ]. Pharmacogenetics, 1997,7: 405 - 409.
  • 4LI T, CHANG C Y, JIN D Y, et al. Identification of the gene for vitamin K epoxide reductase [J]. Nature,2004, 427 : 541 - 544.
  • 5LARISA H, CAVALLARIA, KATHRYN M, et al. Pharmacogenomics of Warfarin dose requirements in Hispanics [J ]. Blood Cells Molecules and Diseases, 2011,46: 147 - 150.
  • 6MIAO L,YANG J, HUANG C,et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin:proposal for a new dosing regimen in Chinese patients [J]. Eur J Clin Pharmacol, 2007,63:1 135 - 1 141.
  • 7YANG J, HUANG C, SHEN Z, et al.Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation [ J ]. International Journal of Clinical Pharmacology and Therapeutics, 2011,49( 1 ) : 23 - 29.
  • 8GIOVANNA DANDREA,ROSA LUCIADAMBROSIO, PASQUALE DI PERNA,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J]. Blood, 2005,105 (2) : 645 - 649.
  • 9PAOLA BORGIANI, CINZIA CICCACCI, VITrORIO FORTE,et al. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians [J]. Pharmacogenomics, 2007,8(11):1 545- 1 550.
  • 10JOHN F,CARLQUIST,BENJAMIN D,et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction [J]. J Thromb Thrombolysis,2010,30:358 - 364.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部